The trial aims to measure AF burden—the percentage of time patients spend in arrhythmia—as its primary efficacy endpoint
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
The work will leverage ProBioGen’s CHO.RiGHT expression platform, powered by its proprietary DirectedLuck transposase technology, alongside PsiBot smart automation
Heart failure affects an estimated 64.3 million people worldwide
Kelun-Biotech and Crescent Biopharma forged a collaboration covering SKB105/CR-003 and SKB118, a PD-1 x VEGF bispecific antibody also known as CR-001
The company is pursuing the accelerated FDA 505(b)(2) approval pathway for its once-daily oral ondansetron formulation
The filing clears the regulatory path for potential first-in-human trials and marks a key advance in the company’s chronic inflammatory disease pipeline
Applications include detailed scientific rationale and supporting clinical evidence
The applications aim to launch Phase Ib/II trials for relapsed/refractory multiple myeloma and primary plasma cell leukemia, respectively
INOVIO remains confident in the therapy’s benefits and intends to meet with the FDA to discuss maintaining eligibility under this pathway
Subscribe To Our Newsletter & Stay Updated
